期刊文献+

不同抗肿瘤治疗方式对PD-L1表达的影响及相关机制

The effect of different anti-tumor treatments on the expression of PD-L1 and related mechanisms
原文传递
导出
摘要 程序性死亡受体-1/配体-L1(PD-1/PD-L1)抑制剂作为免疫治疗的新型药物,常与放化疗、靶向治疗等联合应用到各种恶性肿瘤的治疗中,目前认为PD-L1表达率可预测PD-L1抑制剂疗效。而不同的抗肿瘤治疗会对PD-L1的表达产生不同的影响,因此明确不同抗肿瘤治疗方式对PD-L1表达水平的影响以及相关机制显得十分重要。本文总结了不同抗肿瘤治疗方式对PD-L1表达的影响以及其发生机制,指出了肿瘤患者在接受免疫治疗前以及治疗期间,需行二次甚至多次活检来明确肿瘤组织的PD-L1表达情况,以协助临床医师判断是否可以施行联合免疫治疗,帮助患者有更好的生存获益。 In recent years,programmed death receptor-1/ligand-L1(PD-L1)inhibitors are often used in combination with radiotherapy,chemotherapy,and targeted therapy in the treatment of various malignant tumors.It is currently believed that the expression rate of PD-L1 can predict PD-L1 efficacy of L1 inhibitor.This paper reviewed many domestic and foreign studies on the effects and mechanisms of different anti-tumor treatments on PD-L1 expression and found that there are differences in the effects of different treatment options on PD-L1 expression and the mechanisms involved.It is pointed out that before and during treatment,tumor patients need to undergo two or even multiple biopsies to confirm the expression of PD-L1 in tumor tissues,so as to assist clinicians in determining whether to combine immunotherapy,so that patients can have better survival benefits.
作者 叶丽静 虞亦鸣 YE Lijing;YU Yiming(Department of Respiratory and Critical Care,Affiliated Hospital of Ningbo University School of Medicine,Ningbo 315020,China)
出处 《生命的化学》 CAS 2022年第1期56-62,共7页 Chemistry of Life
基金 浙江省自然科学基金项目(2018A610271)。
关键词 PD-1/PD-L1 放化疗 靶向治疗 免疫治疗 PD-1/PD-L1 radiotherapy and chemotherapy targeted therapy immunotherapy
  • 相关文献

参考文献4

二级参考文献20

  • 1孙德彬,留静.顺铂联合吉西他滨对肺癌PD-1/PD-L1途径的影响[J].中国生化药物杂志,2014,34(5):50-53. 被引量:12
  • 2Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-smaU-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol, 2015. pii: S1470-2045( 15)70168-3. doi: 10.1016/$1470-2045(15)70168-3. [Epub ahead of print].
  • 3Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63( 1 ) : 11-30.
  • 4Moro-Sibilot D, Audigier-Valette C, Merle P, et al. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens ( IFCT- 0702: A randomized phase 3 final results study) [ J ]. Lung Canc- er, 2015, 89(2): 139-145.
  • 5Wu P, Wu D, Li L, et al. PD-L1 and survival in solid tumors: A recta-analysis [ J/OL ]. PLoS One, 2015 [ 2015-09-22 ]. http://journals.plos, org/plosone/article? id = 10. 1371/journal. pone.0131403.
  • 6Bobbio A, Alifano M. Immune therapy of non-small cell lung cancer: The future[J]. Pharmacol Res, 2015, 99: 217-222.
  • 7Hanahan D, Weinberg RA. Hallmarks of cancer: the next gener- ation[J]. Cell, 2011, 144(5) : 646-674.
  • 8Lu W, Lu L, Feng Y, et al. Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1surface expression[J]. Oncol Lett, 2013, 5(5) : 1519-1526.
  • 9SznolM, Chen L. Antagonist antibodies to PD-land B7-H1 (PD- L1 ) in the treatment of advanced human cancer response [ J ]. Clin Cancer Res, 2013, 19(19): 5542.
  • 10Qin X, Liu C, Zhou Y, et al. Cisplatin induces programmed death-l-ligand 1 ( PD-L1 ) over-expression in hepatoma H22 cells via Erk./MAPK signaling pathway [ J ]. Cell Mol Biol ( Noisy-le- grand), 2010, 56(Snppl) : 1366-1372.

共引文献116

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部